Shopping Cart
Remove All
Your shopping cart is currently empty
Catumaxomab
😃Good
Catalog No. T78307Cas No. 509077-98-9
Alias LP-000, LP000
Catumaxomab （LP-000） is a rat-mouse hybrid lgG2 monoclonal and bispecific antibody that binds to the antigens CD3 and EpCAM (Epithelial Cell Adhesion Molecule) for the treatment of malignant ascites in cancer patients.
Catumaxomab
Catumaxomab
😃Good
Catalog No. T78307Alias LP-000, LP000Cas No. 509077-98-9
Catumaxomab （LP-000） is a rat-mouse hybrid lgG2 monoclonal and bispecific antibody that binds to the antigens CD3 and EpCAM (Epithelial Cell Adhesion Molecule) for the treatment of malignant ascites in cancer patients.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | - | In Stock | |
| 5 mg | $859 | - | In Stock | |
| 10 mg | $1,380 | - | In Stock | |
| 25 mg | $1,980 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:>95.0% (SDS-PAGE)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Catumaxomab （LP-000） is a rat-mouse hybrid lgG2 monoclonal and bispecific antibody that binds to the antigens CD3 and EpCAM (Epithelial Cell Adhesion Molecule) for the treatment of malignant ascites in cancer patients. |
| In vitro | Catumaxomab inhibits the growth of FaDu tumor spheroids co-cultured with PBMCs in a dose-dependent manner when treated at concentrations ranging from 0 to 5 ng/mL for 3 to 7 days [1]. |
| In vivo | Catumaxomab was administered intraperitoneally to patients with EpCAM-positive cancers and malignant ascites on days 0, 3, 7, and 10 at escalating doses of 10, 20, 50, and 150 μg, respectively. The treatment significantly prolonged puncture-free survival, reduced the number of EpCAM-positive tumor cells and VEGF levels in ascitic fluid, and enhanced the activation of CD4⁺ and CD8⁺ T cells [2]. |
| Synonyms | LP-000, LP000 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | EpCAM/TROP1/CD326 & CD3E |
| Molecular Weight | 146.73 kDa |
| Cas No. | 509077-98-9 |
| Isotype | IgG2a-kappa/IgG2b-lambda |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Catumaxomab | purchase Catumaxomab | Catumaxomab cost | order Catumaxomab | Catumaxomab in vivo | Catumaxomab in vitro | Catumaxomab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.